Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
2025-10-06 · Zydus Lifesciences Limited · original zyduslife.com ↗
Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg Ahmedabad, India, October 6, 2025 Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received NOC (Notice of Compliance) from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg. Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism. ZDS- Liothyronine tablets will be manufactured at Zydus’ plant in Ahmedabad SEZ. Liothyronine tablets had annual sales of 10.9 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025). ###
The release as fetched from its publisher. zyduslife.com ↗